Telomir Pharmaceuticals(TELO.US)

Last Updated 19:00:00 ET
longbridge loading

Telomir Reports Peer-Reviewed Preclinical Telomir-Zn Data Showing Dose-Dependent Survival & Reduced Hepatic Copper

TradingView·
US
TELO
-0.76%
US
ARKG
+3.35%
US
FBT
+0.69%
TradingView·
US
TELO
-0.76%
US
ARKG
+3.35%
US
FBT
+0.69%

Telomir Pharmaceuticals | 10-Q: FY2026 Q1 Revenue: USD 0

Earnings Watch·
US
TELO
-0.76%
Earnings Watch·
US
TELO
-0.76%

Telomir Pharmaceuticals, Inc. 1Q 2026: Revenue $0 EPS $(0.03) — 10-Q Summary

TradingView·
US
TELO
-0.76%
US
PBE
+0.35%
US
LABU
+2.48%
TradingView·
US
TELO
-0.76%
US
PBE
+0.35%
US
LABU
+2.48%

EXCLUSIVE: Telomir Pharmaceuticals Secures FDA Nod For Its Breast Cancer Therapy To Advance Into Human Study

benzinga_article·
US
TELO
-0.76%
US
PBE
+0.35%
US
IHE
+1.29%
benzinga_article·
US
TELO
-0.76%
US
PBE
+0.35%
US
IHE
+1.29%

Teva Signals Confidence With $700 Million Pipeline Push, Buyback Plan

benzinga_article·
US
TEVA
-0.47%
US
TELO
-0.76%
US
BIB
+1.41%
benzinga_article·
US
TEVA
-0.47%
US
TELO
-0.76%
US
BIB
+1.41%

Telomir Pharmaceuticals Completes Acquisition of TELI Pharmaceuticals, Securing Global Rights to Telomir-1 (Telomir-Zn)

Fidelity·
US
TELO
-0.76%
US
XLV
+0.69%
US
ARKG
+3.35%
Fidelity·
US
TELO
-0.76%
US
XLV
+0.69%
US
ARKG
+3.35%

Weekly Buzz: SPRY Gains FDA Nod; EU Expands Kerendia Label; LLY Acquires CNTA; BIIB Snaps Up APLS

rttnews·
US
BAYRY
-0.53%
US
TEVA
-0.47%
US
LABU
+2.48%
rttnews·
US
BAYRY
-0.53%
US
TEVA
-0.47%
US
LABU
+2.48%
© 2026 Longbridge｜Disclaimer